P
Pepscan
Enabling life-improving breakthroughs by mastering peptides
About Pepscan
Pepscan is a leading provider of peptide-based products and services, catering primarily to life science researchers and pharmaceutical companies. The company specializes in constrained peptides and is the inventor of the constraining technology, which enhances the affinity and selectivity of peptides, making them comparable to antibodies in functionality. Pepscan's core offerings include custom peptide synthesis, epitope mapping, and the development of CLIPS peptides, a new generation of biotherapeutics. The company operates in the biotechnology and pharmaceutical markets, focusing on drug discovery collaborations and the development of high-quality cGMP peptides for clinical trials. Pepscan generates revenue through the sale of custom peptides, licensing of its proprietary technologies, and collaborative research agreements. The business model is built on providing specialized, high-value services that meet the stringent requirements of its clients in drug development and research.
Source: Dealroom company dataAt a glance
- Founded
- 1999
- Headquarters
- Lelystad, Netherlands
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Eureka
Series A1 investor entered at this stage
- BBBiox Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pepscan on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pepscan on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.